Public Employees Retirement System of Ohio Takes Position in Edwards Lifesciences Corporation $EW

Key Points

• Public Employees Retirement System of Ohio purchased 185,970 Edwards Lifesciences shares in the second quarter, valued at approximately $16.8 million. Institutional investors collectively own 79.46% of the company.
• Analyst sentiment remains positive, with 17 Buy ratings and six Holds, producing a consensus rating of “Moderate Buy” and an average price target of $100.27.
• Edwards Lifesciences exceeded quarterly expectations with earnings of $0.78 per share versus the $0.74 estimate, while revenue rose 13.6% year over year to $1.74 billion.

Public Employees Retirement System of Ohio bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 185,970 shares of the medical research company's stock, valued at approximately $16,823,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $5,318,092,000. State Street Corp lifted its holdings in Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 4.8% during the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock worth $1,857,934,000 after purchasing an additional 989,533 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $1,274,082,000. Finally, Norges Bank acquired a new position in Edwards Lifesciences in the 4th quarter valued at $803,686,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EW. Wall Street Zen downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Saturday, July 4th. Leerink Partners raised shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. TD Cowen reiterated a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Citigroup boosted their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Finally, Mizuho raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $90.19 on Friday. The company has a 50 day moving average of $89.54 and a 200-day moving average of $85.03. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The company has a market cap of $51.93 billion, a PE ratio of 51.83, a price-to-earnings-growth ratio of 2.37 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same period last year, the firm posted $0.67 earnings per share. The firm's quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the firm's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 4,501 shares of company stock worth $408,213. Corporate insiders own 0.31% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source